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Abstract: Background: To investigate the intraocular pressure (IOP) response following intravitreal injection of triamci-
nolone acetonide. 
Methods: This retrospective consecutive non-comparative case series study included 41 patients (52 eyes) (19 male, 22 
female, mean age 64.1 ± 13.44; range 22 – 85 years) with progressive exudative ARMD (n = 10 eyes) or diffuse diabetic 
macular oedema (42 eyes), who received one or more intravitreal injection(s) of 4 mg triamcinolone acetonide. 
Results: IOP increased significantly (p<0.001) from 16.08 (±3.28) mm Hg (range 12-26 mm Hg) preoperatively to a mean 
maximum of 26.1 (±11.79) mmHg (range 15-80 mm Hg) postoperatively (p<0.001). An IOP rise to values higher than 21 
mm Hg was observed in 28 (53.8%) eyes. Elevation of IOP occurred 7.5 weeks (±7.07) after the injection. All five pa-
tients (11.9%) with a family history of glaucoma developed an IOP rise above the mean maximum level. The post-
injection rise of IOP was statistically independent of gender (p=0.37), but the presence of diabetes mellitus demonstrated a 
marked influence on the rate of a postoperative elevation of IOP (p=0.05). 
Conclusion: The IOP response following IVTA was consistent with previous studies. A family history of glaucoma and a 
history of diabetes mellitus may predispose patients to a greater than average IOP rise following IVTA. Careful IOP as-
sessment for at least 6 months post injection is recommended. 
INTRODUCTION 
  As the clinical application of intravitreal triamcinolone 
(IVTA) evolves, so does the interest in its potential side ef-
fects and safety. IVTA is effective when used for the treat-
ment of cystoid macular oedema caused by diabetic maculo-
pathy [1], central retinal vein occlusion [2], uveitis, post 
cataract surgery macular oedema [3]. As IVTA can be con-
sidered as a therapeutic approach for a large spectrum of 
clinical conditions, knowledge of the subsequent IOP re-
sponse needs to be established, since steroids are associated 
with IOP increase [4]. 
  Currently there has not been a demonstrable long-term 
toxic effect of intravitreal triamcinolone injections. How-
ever, one recognized and established side effect is the eleva-
tion of intraocular pressure (IOP) leading to a secondary 
chronic open angle glaucoma. A steroid induced glaucoma 
may occur in up to 52% of eyes after triamcinolone injection 
[4]. 
  The exact pathophysiology of steroid induced glaucoma 
is not entirely understood. The elevation in intra-ocular pres-
sure is thought to be due to increased resistance to aqueous  
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outflow. Indisputably however, a rise in IOP following in-
travitreal steroid injection does occur, and this has been 
demonstrated by many studies [4-8]. A greater understanding 
of the dynamics of this elevation, including its timing and 
extent, is necessary to enable clinicians to detect an IOP rise 
early and to initiate prompt treatment to prevent permanent 
damage to the optic nerve head. 
  Most of the previous studies were from centres in main-
land Europe and USA, and we have complemented these 
with a British study from a large centre in the South-East of 
England with a predominantly Caucasian population. 
METHOD 
  The retrospective interventional case series study in-
cluded 41 patients (52 eyes) (19 men, 22 women; 21 right 
eyes 31 left eyes) who consecutively received one or more 
injections of 4 mg intravitreal triamcinolone in topical anaes-
thesia and had a minimal follow-up of three months. All pa-
tients were Caucasian. The injection was given to patients 
who had reduced visual acuity due to either exudative macu-
lar degeneration with subfoveal neovascularization (n = 10 
eyes) or diffuse diabetic macular oedema (n = 42 eyes). 
Eleven patients (11/41) received the intravitreal cortisone 
injection in both eyes, with a time interval of 1 to 6 months 
between the injections. Mean age was 64.07 (13.44) years 
(range 22-85; median 53.5 years). All patients were fully 
informed about the potential side effects of the therapy and 
signed an informed consent. 
  Two patients (0.05%) had primary open angle glaucoma 
(POAG) before inclusion into this study. Arterial hypertension 
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study had a history of an elevation of IOP during topical or 
systemic treatment before. 
  All patients received an intravitreal injection of 4 mg of 
crystalline triamcinolone acetonide in 0.1 ml Ringer’s solution 
in the minor operating theatre. The solution was prepared by 
the hospital’s pharmacy removing the solvent agent. The in-
jection was administered transconjunctivally under topical 
anesthesia with G. Amethocaine 1% after a paracentesis had 
been performed to decrease the volume of the globe. Using 
applanation tonometry, IOP was determined before, and at 
intervals of 2 - 4 weeks after the injection. 
  The mean follow up time for the patients was 7.23 (+/-
2.11) months with a minimum of 1 month after the first injec-
tion. Topical anti-glaucomatous topical medication was initi-
ated if ocular hypertension occurred (i.e. if a pressure reading 
above 21mmHg was measured). 
  The normally distributed data was analyzed using an un-
paired t-test. For interindividual comparisons only one ran-
domly selected eye per patient was taken for statistical analy-
sis. For intraindividual comparison, the four patients with both 
eyes treated were included in the analysis. 
RESULTS 
  Intraocular pressure increased significantly (p<0.001) from 
16.08 (3.284) mm Hg (range 10-26 mm Hg) to a mean maxi-
mum of 26.1 (11.79) mm Hg (range 15-80 mm Hg) postopera-
tively (Fig. 1). The differences between the IOP measurements 
before the injection and the postoperative examinations were 
significant (p<0.05) for the examinations performed 1 week or 
later after the injection. 
  A rise in IOP to values higher than 21 mm Hg was ob-
served in 28 (53.8%) eyes. The elevation usually occurred 
after 7.5 weeks (+/-7.07). 
  One of the two patients with a current diagnosis of POAG 
demonstrated an IOP rise warranting treatment, the other 
needed no additional treatment. 
  The post-injection rise of IOP to values higher than 21 mm 
Hg was statistically independent of sex (p=0.37). The presence 
of diabetes mellitus however, demonstrated a marked influ-
ence on the rate of a postoperative elevation of IOP (p=0.05). 
  Within the group of patients with a postoperative rise of 
IOP, in all but one eye, IOP could be lowered to normal levels 
with topical medication alone without developing glaucoma-
tous optic nerve head changes (Fig. 2). 
  One eye developed an elevation of IOP to 80mmHg fol-
lowing IVTA. An anterior chamber paracentesis was promptly 
performed resulting in an effective reduction in pressure to 21 
and then to a final IOP of 12. 
  All eyes which developed a secondary ocular hypertension 
after a second intravitreal injection of triamcinolone acetonide 
had also shown a rise in IOP after the first intravitreal injec-
tion. In the absence of a pressure rise after the first injection, 
no eyes showed an increase in IOP after a second injection 
was performed. 
  Eight (80%) of the ten patients who received an intravitreal 
injection of triamcinolone acetonide into both eyes with a time 
interval of 3.5 to 6 months between the injections, developed 
ocular hypertension in both eyes at about the same time after 
the injection (mean 6.7 weeks). 
  All five patients (11.9%) in the study with a positive fam-
ily history of glaucoma developed an IOP rise above 21 
mmHg. The IOP-time relationship is shown in Table 1. 
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Fig. (1). Scatter plot of initial IOP versus maximum IOP following IVTA. 
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Table 1.  The Relationship between Mean IOP Rise and Time 
Following IVTA 
 
 Mean  IOP  mmHg 
Baseline 16.08  (3.3) 
1 month  18.4 (7.1) p<0.05 
3 months  18.2 (7.3) p<0.05 
6 months  16.9 (4.4) 
 
DISCUSSION 
  The findings of this British study from a predominantly 
Caucasian population in the South-East of England concur 
with previous studies from Europe and USA [4-8]. 
  One of the major side effects of intravitreal injection of 
triamcinolone is a steroid induced elevation of IOP [5,9,10]. 
The mechanism by which this happens is not completely 
understood. Immediately after the injection, there is said to 
be an expansion of eye volume and a corresponding increase 
in the rigidity of eye, as demonstrated by the Friendenwald 
Equation [11]. 1 week to 2 months following injection in 
40% of patients, the increased resistance is thought to be due 
to a change in morphological and mechanical changes in the 
trabecular meshwork and most IOP changes return to base-
line within 3-5 months. In 1% of patients, IOP fails to return 
to baseline, and although filtration surgery is popular, some 
treat the cause rather than effect and advocate vitrectomy for 
uncontrolled IOP [12]. 
  The result of the present study showed that a rise in IOP 
to values higher than 21 mm Hg can be expected to occur in 
53.8% of eyes. This is comparable to results found from 
other large studies which looked at the incidence of IOP rise 
with IVTA [4,7]. 
  A predictive factor for the rise in IOP may have been the 
presence of glaucoma before the injection. However, there 
were not enough cases with underlying POAG in the cohort 
to study the statistical significance of this properly. Other 
parameters such as gender did not show a marked influence 
on frequency and amount of elevation of IOP. The presence 
of diabetes mellitus however, demonstrated a marked influ-
ence on the rate of a postoperative elevation of IOP (p<0.05). 
  From a clinical standpoint it is important that in all but 
one eye, the IOP could be controlled by topical anti-
glaucoma treatment, or returned to normal values after the 
intravitreal steroid crystals had resolved about 6 months after 
the injection. Furthermore, it is important to note that a rise 
in IOP after a second intravitreal injection did not occur if 
there was not one found after the first. 
  Unexpectedly, three of the patients who received in-
travitreal steroid injections in both eyes had an IOP rise 
above 21mm Hg in one eye only. The reason for this is not 
clear. 
  The dose of steroid used in the present investigation was 
the same as other clinical studies reporting on the intravitreal 
injection of triamcinolone acetonide [1, 2, 11, 13, 14-19]. As 
expected, the incidence of IOP rise was found to be similar 
to these studies. Jonas et al. [10] found the incidence of IOP 
rise to be 50% following a dose (25 mg) of triamcinolone 
acetonide and the IOP was controlled following treatment 
without the development of major damage to the optic disc. 
This finding is comparable to other studies which used a lower 
of dose of 4mg of IVTA. Although, there is thought to be a 
linear dose-dependent IOP response immediately following an 
injection, as demonstrated by the Friendenwald equation [11] 
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the precise mathematical relationship between steroid dose and 
subsequent IOP response over time is yet to be determined. 
  The aetiology of steroid induced glaucoma is not entirely 
understood. There is some evidence to suggest that the accu-
mulation of glycosaminoglycans in the extracellular matrix 
(ECM) of the trabecular meshwork or increased production of 
trabecular meshwork induced glucocorticoid response (TIGR) 
protein may be responsible for this. However, in a study by 
Kee at al there was found to be no relation between the TIGR 
gene and steroid induced glaucoma [6]. None of the patients in 
the study with steroid induced glaucoma were found to have 
the TIGR gene mutation. Furthermore, a study by Fingeret et 
al. showed that variations in the MYOC gene (the animal ver-
sion of the TIGR gene) did not seem to be responsible for the 
development of steroid induced glaucoma [20]. The ECM 
changes are very likely under control of transforming growth 
factor-beta2 (TGF-beta2), which is found at high concentra-
tions in the aqueous humor of patients with primary open-angle 
glaucoma [21, 22]. Additional factors are thrombospondin-1, 
which activates TGF-beta2 in vivo, and connective tissue 
growth factor, which is an important downstream mediator of 
the effects of TGF-beta2 on trabecular meshwork ECM turn-
over. In contrast, bone morphogenetic protein-7 (BMP-7) 
strongly antagonizes fibrogenic actions of TGF-beta2 on hu-
man trabecular meshwork cells, indicating that a pharmacol-
ogical modulation of BMP-7 signaling might be a promising 
strategy to treat primary open-angle glaucoma [21]. The effect 
of TGFbeta2 and glucocorticoids on cultured trabecular mesh-
work cells show typical changes in formation of ECM compo-
nents and of stress proteins. Dexamethasone and oxidative 
damage also lead to increase of trabecular meshwork inducible 
glucocorticoid response (TIGR) protein [23]. 
  In the present study, all five patients (11.9%) with a posi-
tive family history of glaucoma developed an IOP rise above 
21 mmHg. This suggests that steroid-induced glaucoma may 
be hereditary or a family history of glaucoma may predispose 
someone to higher IOP rise following IVTA. 
  In conclusion, the data from this study suggest that the in-
travitreal injection of triamcinolone acetonide at a dosage of 
4mg leads to a secondary ocular hypertension in about 54% of 
the eyes treated. The rise in IOP is reversible at 6 months after 
the injection and can almost always be controlled by topical 
hypotensive medication alone. A rise in IOP following IVTA is 
common and poses a strong argument in favour of treating all 
patients with ocular hypotensive medication both pre and post 
operatively. It also underlies the importance of informing pa-
tients about this risk when consenting pre-operatively. A family 
history of glaucoma should be elicited in all patients, as this 
may be a predisposition to higher IOP rise following IVTA. 
  Further research is required to scientifically establish the 
aetiology of steroid-induced glaucoma and target possible areas 
of prevention and treatment. 
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